231 related articles for article (PubMed ID: 23045227)
1. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
3. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
4. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
[TBL] [Abstract][Full Text] [Related]
5. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
7. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
[TBL] [Abstract][Full Text] [Related]
8. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
[TBL] [Abstract][Full Text] [Related]
9. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
10. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
[TBL] [Abstract][Full Text] [Related]
12. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.
Ruyssen-Witrand A; Rouanet S; Combe B; Dougados M; Le Loët X; Sibilia J; Tebib J; Mariette X; Constantin A
Rheumatology (Oxford); 2013 Apr; 52(4):636-41. PubMed ID: 23264555
[TBL] [Abstract][Full Text] [Related]
13. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
14. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.
Couderc M; Gottenberg JE; Mariette X; Pereira B; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Soubrier M;
Rheumatology (Oxford); 2014 Oct; 53(10):1788-93. PubMed ID: 24821852
[TBL] [Abstract][Full Text] [Related]
15. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
16. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Marcelli C; Bardin T; Pane I; Baron G; Mariette X
Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
[TBL] [Abstract][Full Text] [Related]
17. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
[TBL] [Abstract][Full Text] [Related]
18. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
[TBL] [Abstract][Full Text] [Related]
19. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]